ABSTRACT
INTRODUCTION
MM is a cancer of terminally differentiated B lymphocytes or PC [1, 2] . It accounts for over 10% of all hematologic malignancy and 2% of annual cancer-related deaths [3, 4] . The American Cancer Society estimates that almost 21,000 new cases of While MM can present as an isolated site of soft tissue or bone disease (plasmacytoma), the overall majority of patients present with multiple sites of bone disease, hence the name "multiple" myeloma [5] . The homing process, characterized by adhesion of circulating cells to vascular endothelium, transendothelial migration, penetration of the basement membrane and ECM and, finally, localization and retention into a niche on the base of a chemotactic gradient, is therefore crucial in mediating MM pathogenicity [7] .
The CRAB criteria for diagnosis of symptomatic MM (hyperCalcemia, Renal impairment, Anemia and Bone disease) as well as the common finding of hypogammaglobulinemia and subsequent predisposition to recurrent infections can all be ascribed to proliferation of the malignant clone in the BM, recirculation of MM cells with homing to distant bony site and their maladaptive interaction with cellular elements present in the BM, including osteoclasts [6] .
The interaction of MM cells with BMSC and ECM components in the BM microenvironment has been proven to sustain MM cell proliferation, provide MM cells with a survival advantage and be responsible for drug resistance to chemotherapeutic agents [7] .
In this perspective, understanding the mechanisms of MM cell trafficking is crucial to further understand the pathophysiology of MM in order to design novel therapies capable of successfully targeting MM cells in their environment, disrupt the vicious MM-BMSC loop and finally help curing MM patients.
In this review, we will discuss the role of chemokines in homing of MM cells to BM; the molecules involved in adhesion and survival within the BM; proteases responsible for ECM invasion and seeding to distant bone sites; the available therapeutic armamentarium and future treatment perspective.
HOMING TO THE BONE MARROW: THE SDF-1/CXCR4 AXIS IN HEALTH AND DISEASE

Ontogenesis of long lived plasma cells
Long lived PC are a key element of immunological memory, being responsible for the maintenance of sustained, low titer, high affinity antibody production [8, 9] . Upon encounter with an appropriate T cell-dependent antigen, B cells form germinal centers (GC) in secondary lymphoid tissues, supporting the formation of plasmablasts [10, 11] . These enter circulation and home to different sites in a process strictly regulated by chemokines and adhesion molecules [12] . The vast majority of post-germinal PC secrete high titer, high affinity antibody over a short period of time, being doomed to die after 3-7 days upon antigen encounter [12] . The tightly regulated apoptosis of short lived PC is an effective mechanism to ensure suppression of antibody production and avoid side effect from prolonged humoral response, including autoimmunity [13] [14] [15] .
On the contrary, a subpopulation of GC derived plasmablasts homes to the BM where they survive for years and ensure long term specific antibody production, key to maintain an adequate antigenic memory. These cells are named long lived PC. They are typically non-recirculating, IgG secreting PC [8, 12, 16] .
It has been observed that while these cells are characterized by sustained survival in vivo, ( Page number not for citation purposes) apoptosis ensues quickly ex vivo [9, 17] . However, long lived PCs can be rescued ex vivo by supplementation of media with stromal cellderived factor 1 (SDF-1) and interleukin 6 (IL-6).
Along the process of B cell differentiation to plasma cell, B lymphocytes undergo rearrangement of their pool of chemokine receptors, downregulating CXCR5 and CCR7, while upregulating CXCR4 and maintaining functional CCR3, CXCR6 and CCR 10. This modified asset of receptors results in decreased responsiveness to B and T-cell chemokines such as CCXCL13, CCL12 and CCL19 and increased sensitivity to SDF-1 gradient [18] [19] [20] .
Initially identified as a growth factor for pre-B cells, SDF-1 has been subsequently shown to have a key role in multiple steps of B cell-poiesis [21] [22] [23] . Also know as CXCL-12, SDF-1 is a chemokine constitutively expressed by BMSC and exerts its function as chemoattractant and growth factor by binding its cognate receptor CXCR4 [20, 24] . The latter belongs to the family of G protein coupled receptors, also known as 7 transmembrane domain proteins, and is expressed by B cells throughout different stages of their ontogenesis: in pre-B cells, it mediates localization to dedicated BM niches; in mature B cells, it is crucial for appropriate organization of germinal centers; in PC it is a fundamental factor to guide homing to the BM [20, 22, 25] . Once in the BM, long lived PC localize in close proximity with a subset of BMSC secreting high levels of SDF-1 [22] . Recruitment and accumulation of PC in the BM has been shown to be significantly delayed in mice genetically engineered to lack expression of CXCR-4 in the B cell lineage [26] . However, a consistent number of long-lived PCs was still present in the BM of such mice, therefore suggesting redundant mechanisms for homing and retention of PC beyond the SDF-1/CXCR4 axis. The authors suggested the existence of two different ontogenic processes for long-lived PC: the classic post-GC differentiation into plasma blasts expressing high level of CXCR-4 and being dependent on SDF-1 gradient for homing and retention into the BM; and a second population of plasma-blasts capable of homing to the BM in a CXCR4/SDF-1 independent mechanisms and undergoing terminal differentiation to long-lived PC in situ. 
THE SDF-1/CXCR4 AXIS IN MULTIPLE MYELOMA
Nowakowski et al. showed that circulating PC are present in more than 70% of newly diagnosed MM patients and represent an independent predictor of survival [30, 31] . In order to reach the favorable environment of the BM niche, circulating MM cells need to adhere to endothelial cells, cross the endothelial lining and migrate to the BM, a process collectively known as homing [7] .
Flow cytometry studies on primary cells of MM patients obtained from BM, peripheral blood and extra medullary sites showed CXCR4 to be present in 70% of BM MM cells and 100% MM from peripheral blood or extramedullary sites [32] . In this particular study, a subset of malignant cells was capable of spontaneous migration, independently from chemotactic gradient, and such capacity correlated with more aggressive disease, advanced stages and tendency to extramedullary localization and leukemic phase.
Multiple myeloma cells have been shown to be dependent on the SDF-1/CXCR4 axis for BM homing, ECM and transendothelial migration and survival [33, 34] . As their normal counterpart, MM cells express CXCR4 and its interaction with SDF-1 is responsible for adhesion to vascular cell adhesion protein 1 (VCAM-1), ECM components including fibronectin, and endothelial cells via expression of α4β1 [35, 36] . Interestingly, SDF-1 level was significantly higher in the BM milieu of patients with MM compared to healthy donors [35] .
As the interaction of MM with the BM microenvironment has been shown to be crucial for pathogenicity, MM cell survival and drugresistance, recent years have witness a growing interest in understanding the mechanisms underlying SDF-1-mediated recruitment of MM cells to the BM.
In multiple myeloma cells, SDF-1 induces (Page number not for citation purposes) relocalization and polarization of CXCR4, followed by pseudopodia formation, leading to chemotaxis of MM cells toward the source of SDF-1 [35] . In vitro, the dose response to SDF-1 was distributed according to a bell-shaped curve, with peaked effect around 30nM and decreased chemotaxis for higher concentration of SDF-1. This mechanism was thought to be responsible for retention of MM in the BM where high concentrations of SDF-1 are achieved. SDF-1 causes internalization of CXCR4 in vitro and primary cells from MM patients showed higher surface expression of CXCR4 while circulating in the peripheral blood, when compared to BM resident MM cells, suggesting a potential negative feedback loop between SDF-1 and CXCR4.
CXCR-4 was proved necessary for SDF-1 induced migration of MM cells as pharmacologic inhibition of CXCR4/SDF-1 binding, via anti CXCR-4 monoclonal antibody (mAb) or CXCR4 knockdown, abolished SDF-1 induced migration [35] . Differently from hematopoietic stem cells (HSC), the phosphoinositide 3-kinase inhibitor (PI3K) and extracellular signal-regulated kinase/mitogenactivated protein kinase (ERK/MAPK) pathways were shown to be activated downstream CXCR4/SDF-1 interaction. Inhibition of CXCR4 signaling via the Gi protein inhibitor PTX abolished phosphorylation of ERK and AKT. The PI3K inhibitor LY294002 reproduced a similar effect with inhibition of ERK and AKT phosphorylation while the MAP/ERK kinase (MEK) inhibitor PD098059 only affected phosphorylation of ERK 1/2, therefore suggesting a hierarchy with PI3K upstream of ERK/MAPK.
De Gorter et al. showed that SDF-1 stimulation of MM cells results in activation of the small GTPase RalB which in turn is necessary, but not sufficient to drive SDF-1 induced chemotaxis [37] . The authors showed that activation of RalB is independent of cytosolic kinases Lyn/Syk, phospholipase C (PLC), Bruton's tyrosine kinase (Btk), PI3K and Ras and postulated β-Arrestin and p38 pathway to be responsible for SDF-1-mediated RalB activation [38, 39] .
RhoA and Rac1, members of the Rho guanosine triphosphatase(GTPase) family, are involved in mediating MM adhesion and SDF-1-induced chemotaxis, as well [40] . Gene expression profiling and flow cytometry in MM cell lines and primary myeloma cells showed RhoA and Rac1 to be expressed at a significantly higher level in MM when compared to bone marrow plasma cells from control individuals [41] . Rho-associated protein kinase (ROCK) is a major effector molecule along the RhoA signaling pathway [42] [43] [44] . ROCK and Rac1 are involved in MM cell adhesion to endothelium and fibronectin and in triggering MM-BMSC binding via a very late antigen 4/vascular cell adhesion molecule 1 (VLA 4/VCAM-1)-dependent and leukocyte function-associated antigen 1/intracellular adhesion molecule 1 (LFA-1)/ICAM-1-independent mechanism [41] .
Chemotaxis along SDF-1 gradient was dependent upon RhoA, but not Rac1. Confocal microscopy studies showed that SDF-1-induced actin polymerization and polarization were substantially reduced by the ROCK inhibitor Y27632, while Rac1 blockade via its inhibitor NSC23766 had a less prominent effect on the former and did not affect the latter. Moreover, ROCK, but not Rac1 inhibition, resulted in increased dephosphorylation of myosin light chain (MLC), a key molecule in the regulation of contraction and relaxation of actin [45] .
Pharmacologic inhibition of either ROCK or Rac1 in a murine model resulted in delayed MM cell exit from circulation and bone marrow engraftment, thus further confirming the role of both molecules in MM cell homing to the BM niche [41] .
In a similar mouse model, significantly reduced homing of intravenously injected MM cells to bone marrow niches was obtained by pharmacological inhibition of SDF-1/CXCR4 interaction by AMD3100 (plerixafor, AnorMED, Toronto, ON, Canada), a selective, reversible bicyclam antagonist of SDF-1 [35] .
THE BONE MARROW MICROENVIRONMENT: A SURVIVAL NICHE FOR MM
The bone marrow microenvironment is composed of a cellular and a non-cellular component. The former includes stroma cells, endothelial cells, hematopoietic stem cells and pluripotent precursors, adipocytes, osteoblasts and osteoclasts; the latter is the pool of ECM proteins such as laminin, fibronectin and collagen [46, 47] .
The binding of MM cells to BM cells has been (Page number not for citation purposes)
reported to increase autocrine and paracrine production and secretion of molecules involved in survival, proliferation and neoangiogenesis such as IL-6, SDF-1, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1), tumor necrosis factor α (TNF-α) and transforming growth factor β (TGF-β) [48] [49] [50] . This bidirectional positive feedback loop between MM cells and BMSC is sustained by the induction of several pro-survival signaling pathways, including nuclear factor kB (NF-kB), MEK/ERK pathway, Janus kinase/signal transducers and activator of transcription 3 (JNK/STAT3) pathway, PI3K/AKT pathway [17, 36, 51] . The downstream effects of these signaling pathways include upregulation of cyclin D1; induction of antiapoptotic, multi dimers Bcl proteins; stimulation of osteoclastogenesis and inhibition of osteoblast differentiation; induction of adhesion molecules (i.e., ICAM-1), pro-survival cytokines (i.e., IL-6), neo-angiogenesis factors (i.e., VEGF) and matrix metalloproteinases (i.e., MMP-9 and MMP-1) [7, [52] [53] [54] [55] .
Importantly, the adhesion of MM cells to BMSCs mediates cell-adhesion mediated drug resistance (CAM-DR) while some of the chemokines, including IL-6, have been shown to cause drug resistance by mechanisms independent from cell-cell contact [49, 51, [55] [56] [57] [58] .
MM-BMSCs interaction occurs via a plethora of adhesions molecules as CD44, VLA 4 and 5, LFA-1, ICAM-1, VCAM-1 and syndecan-1 or CD138. The latter is a transmembrane proteoglycan strongly expressed by terminally differentiated plasma cells and MM cells that mediates adherence to ECM via binding of type I collagen. The CD138-type I collagen interaction triggers expression of matrix metalloproteinase 1 (MMP-1) which has been shown to be crucial for ECM reabsorption and tumor invasion [52, 59, 60] .
Disruption of the normal balance between osteoclast and osteoblast activity in the MM niche is fundamental to perseverate MM survival and proliferation and is a major determinant of MMrelated morbidity including pathologic fractures and hypercalcemia [61, 62] . MM is characterized by increased number and activity of osteoclasts and impairment of new bone deposition due to suppression of osteoblast function [63, 64] . Several humoral factors are involved in mediating the maladaptive MM-osteoclast loop, including IL-6, receptor activator of NF-κB ligand (RANKL), B-cell activating factor (BAFF), VEGF and dickkopf (DKK)-1 [65, 66] .
A relative excess of the receptor activator of NF-κB ligand (RANKL) in comparison to the decoy receptor osteoprotegerin (OPG) was demonstrated to play a major role in determining an unbalance between bone reabsorption and deposition and to be a prognostic factor for bone disease in MM [63, 67, 68] .
Given the hypoxemic nature of the bone marrow, there is growing interest in the role of HIF-1 in MM progression, neoangiogenesis and trafficking [69] [70] [71] [72] [73] . Interestingly, HIF-1 and 2 induces expression of CXCL-12 with a tentative teleological goal of attracting circulating stem cells to ischemic areas in order to guarantee tissue repair [74] . HIF-1 is also responsible for inducing CXCR4 in normal and malignant cells, potentially contributing to bone marrow metastatic spread [75, 76] . Immunohistochemistry studies found HIF-1α and HIF-2α to be frequently overexpressed in primary MM cells and their expression to correlate with VEGF production and neoangiogenesis [77] . Interestingly, HIF-2α was found to be a positive regulator of aberrant expression of CXCL12 in MM cell lines [78] .
RECIRCULATION TO DISTANT SITE: THE ROLE OF METALLOPROTEINASES AND INTEGRINS
MM cell homing is a complex multistep process that sequentially requires tenacious adhesion of circulating cells to the endothelial surface; migration through endothelium, basement membrane, subendothelial space and extracellular matrix; and, finally, localization and retention into the bone marrow niche. MMPs are a family of multidomain, zinc-dependent, endopeptidases which have been implicated in both physiological (leukocyte extravasation, tissue remodeling) and pathological processes (metastasis, tissue invasion) [79] [80] [81] . MMPs exist in two forms: as zymogenic enzymes that are secreted in an inactive form and undergo activation by cleavage, or as integral transmembrane proteins, namely membrane-type MMPs (MT-MMP) [82] [83] [84] . The activity of MMPs is modulated in a sophisticated manner at different (Page number not for citation purposes) levels: beyond transcriptional and translational control, MMP function is affected by stereotactic interaction with other ECM proteins, including tissue inhibitors of MMPs (TIMP), a family of small molecular weight proteins whose function is reversible inhibition of MMPs [85] . The fine equilibrium between MMPs activity and their counter-regulatory mechanisms defines the outcome [86] [87] [88] [89] .
In vitro, primary MM cells and BMSC from MM patients produce an excess of several MMPs, including MMP-1, MMP-2, MMP-8, MMP-9, MMP-13 and MTI-MMP when compared to their normal tissue counterparts [52, 60] . In vitro experiments with primary MM cells and MM cell lines using Matrigel, an extracellular matrix extract that mimics in vitro the composition of basement membrane, showed that migration was dependent on CXCL12 and substantially inhibited by anti-CXCR4 mAb, CXCR4-CXCL12 binding inhibitors and broad metalloproteinase inhibitor GM6001 [90] . Further studies showed that exposure to CXCL-12 resulted in increased secretion of MMP-9 by MM cells and that specific blocking antibodies against MMP-9 or the use of TIMP-1, a naturally produced inhibitor of MMP-9, significantly abrogate CXCL-12 induced MM migration. Exposure of MM cells to CXCL-12 also resulted in increased expression of MT1-MMP and its discrete polarization along a unique site on the cell membrane. Inhibition studies with blocking mAb and specific pharmacologic inhibitors, showed MT1-MMP to also play a role in mediating migration of MM cells through Matrigel. Further in vitro experiments proved transendothelial migration of MM cells to be dependent upon an intact CXCL-12/CXCR4 axis and to be mediated by MMP-9. A second mechanism by which MMP-9 is thought to contribute to metastatic spread and MM progression, is its ability to release matrix-bond VEGF-A, resulting in VEGF-A binding to its receptor and initiation of neoangiogenesis cascade [91] .
Mouse models have been used to further investigate the putative role of MMPs in MM trafficking and disease progression. In 5T2MM bearing mice, treatment with SC-964, a broad MMP inhibitor, resulted in a significant decrease in burden of disease with reduction in osteolytic lesions and decreased neoangiogenesis when compared to untreated mice, suggesting a pivotal role for MMP in MM pathogenesis [92] .
MM cells express a wide array of integrins, including α4, α5, αv, β1, β2, β3 and β7 whose activity is regulated both by binding with ECM and by inside-out signalling [54, 93] . The expression of several integrins in MM cells has been shown to be regulated by cytokines, chemokines and oncogenes [94, 95] .
Integrins VLA-4 (α4 β1), VLA-5 (α5 β1) and αvβ3 have been long known to mediate MM homing to the BM; malignant cell trafficking and drug resistance [56, [96] [97] [98] [99] . More recently, a role for integrin β7 as a negative prognostic factor for survival and predictor of poor response to standard and novel therapy has been established in MM [100] . Integrin β7 was identified as a downstream target of the oncogene C-MAF, which is overexpressed in almost half of MM patients either via genetic rearrangement (translocation t(14;16)) or due to paracrine stimulation along the BAFF/APRIl/TACI (B-cell activating factor / a proliferation-inducing ligand / transmembrane activator and calcium modulator and cyclophilin ligand interactor) axis. In vitro studies showed that knock down or mAb-mediated blockade of integrin β7 resulted in diminished MM cell line adhesion to fibronectin, E-cadherin and BMSCs; reduced capacity of invasion of Matrigel and of migration along an SDF-1 gradient and increased sensitivity to standard and novel chemotherapy agents such as melphalan and bortezomib. Moreover, integrin β7 was implicated in inducing VEGF, macrophage inflammatory protein 1β (MIP-1β) and interleukin 1β (IL-1β) secretion by MM and BMSC, suggesting a role in mediating neo-angiogenesis and osteoclast activity.
Consistent with in vitro studies, knock down of integrin β7 resulted in delayed homing and tumor engraftment in a murine model as well as decreased MM-related neoangiogenesis.
ANIMAL MODELS IN MM TRAFFICKING
In order to better understand the pathophysiologic mechanisms behind MM homing to the BM and cell trafficking, animal models have been used as a tool to recapitulate the natural history and mechanicistic evolution of MM. Nevertheless, the technological difficulties related to following real time the circulation of cancer cell as well as the intrinsic differences between the murine and human bone marrow
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microenvironment had made it difficult to satisfactory reproduce MM in animals [101] .
The 5T2MM is a well characterized myeloma cell lines obtained by C57Bl/KaLwRij mice. When elderly, these mice spontaneously develope a population of cells whose behavior recapitulate human MM. When injected intravenously in younger syngeneic mice, these cells are capable of homing to the BM, producing osteolytic lesions, secreting a monoclonal serum Ig and inducing neoangiogenesis [102] [103] [104] . The 5T2MM mouse model has been used to evaluate the effect of MMP inhibition in MM cell homing, survival and proliferation. Although the authors were able to assess BM homing, neoangiogenesis and disease burden, no real time monitoring of distribution of MM cells could be achieved with this model [92] .
The plasmacytoma mouse model, obtained by subcutaneous injection of human MM cells in immunodeficient mice, was the first animal model to utilize human MM cells [105] . Unfortunately, no data about the interaction of MM cells with their natural environment, the bone marrow, could be obtained by this model. Moreover, by definition, homing and trafficking could not be evaluated in a plasmacytoma model [106] . Intravenous injection of MM cells in severe combined immunodeficient/non obese diabetic (SCID/NOD) mice provided a considerable improvement in the validity of animal model for assessment of trafficking as it would recapitulate the processes of multi-site homing of MM cells. However, rapid, accurate and real time evaluation of those processes could not be obtained [101] .
The implementation of novel optic techniques based on luminescence and fluorescence provided the unique opportunity to visualize real time and study the kinetics of homing and re-trafficking of MM cells [107] .
Irradiated, SCID/NOD mice injected intravenously with luciferase positive (Luc+) or lentivirally transfected GFP-luciferin-Neo MM.1S cells (a widely used, MM cell line) were used to study the effect of the SDF-1 inhibitor AMD3100 on MM cell trafficking and homing to the BM [35, 108] .
The kinetic of homing of malignant cells was followed at close interval by means of whole body, real time bioluminescence [109, 110] . In mice treated with combination of bortezomib and AMD3100, in vivo flow cytometry provided real time detection of apoptosis in circulating MM cells without need for blood draws [108] .
Alsayed et al. further confirmed their findings by using Balb/c mice injected with fluorescently labeled MM.1S cells. In vivo flow cytometry allowed live monitoring of myeloma cells as they exit the circulation and localize to the bone marrow, while fluorescence confocal microscopy provided high resolution images throughout the intact animal skull and direct visualization of the bone marrow niche [111] . This same mouse model was used by Neri et al. to evaluate the role of integrin β7 in BM homing [100] . SCID mice subcutaneously injected with wild type and ITGB7 silenced MM.1S cells provided the authors the opportunity to evaluate the effects of integrin β7 silencing on proliferation of MM cells in vivo.
In vivo flow cytometry and fluorescence confocal microscopy was also used in SCID mice intravenously injected with fluorescent MM.1S cells to address the impact of the ROCK inhibitor Y27632 and the Rac1 inhibitor NSC23766 [41] .
THE
CORNER OF THE PHARMACOLOGIST: HOW TO DISRUPT MM TRAFFICKING
The interaction between MM cells and BMSCs mediates not only MM cells proliferation and survival, but also drug resistance. Recent efforts have been invested in pharmacologically targeting the MM-BMSC interaction to circumvent the pro-survival and growth advantage conferred by the BM microenvironment, overcome standard chemotherapy resistance and to improve therapy against MM.
Given its key role in mediating homing and retention of MM cells in the bone marrow, the CXCR4-SDF-1 axis was the natural target of such therapies.
In vitro studies showed the SDF-1 antagonist AMD3100 to cause sensitization of MM cells to novel and standard chemotherapy agents including bortezomib, melphalan, doxorubicin and dexamethasone [108] . In the presence of BMSC, (Page number not for citation purposes) the co-treatment with AMD3100 resulted in significant inhibition of phosphorylation of AKT in MM cells treated with bortezomib, providing a molecular mechanism for the improved bortezomib effect in the presence of AMD3100. Azeb et al. showed that in a murine model, treatment with AMD3100 caused mobilization of MM cells to the peripheral blood with delayed kinetics when compared to mobilization of hematopoietic stem cell, suggesting that a timely planned administration of chemotherapy agents after AMD3100 could spare HSC and be an effective anti-MM therapy. Mice treated with AMD3100 showed neither a more aggressive course of disease nor an increase in extramedullary engraftment of MM cells. Moreover, combinatory treatment with bortezomib and AMD3100 resulted in increased overall effectiveness of bortezomib with a significant percentage of circulating MM cells undergoing apoptosis and with no evidence of increased toxicity against HSC [108] .
Currently AMD3100 has been successfully used in phase I, II and III clinical studies to aid mobilization of CD34+ positive cells in patient undergoing harvesting for autologous bone marrow transplantation [112, 113] . No significant early or delayed toxicity or inadequate HSC engraftment were noticed with the use of AMD3100 alone or in combination with G-CSF [114] [115] [116] [117] [118] . Indeed, the addition of AMD3100 to G-CSF was proved to successfully mobilize CD34+ cells in patients with hematologic malignancies, including MM, who had previously failed mobilization with cytokines alone [119] .
Noticeably, the use of AMD3100 was not associated with significantly increased mobilization of MM cells to the peripheral blood or with tumor contamination of the CD34 apheresis products [120] . In the context of the data reported by Azeb et al, this observation could be the result of delayed mobilization of MM cells when compared to HSC after administration of AMD3100.
A phase I/II clinical trial of combination of plerixafor and bortezomib is currently undergoing in relapsed/refractory MM patients and several clinical trials of AMD3100 in combination with standard and novel anti-MM agents are currently enrolling.
T140 is a 14 amino acid, CXCR4 antagonist derived from a naturally occurring horseshoe crab produced molecule. Comparative studies showed AMD3100 to have weak partial agonist activity upon binding of CXCR4 while T140 functions as an inverse agonist and produces no signalling upon binding to the receptor [121, 122] . Head to head comparison of the two molecules in MM cell lines showed a transient pro-proliferative and prosurvival effect caused by AMD3100, but not T140, followed by a sustained anti-proliferative action of both [123] . In this perspective, T140 could have an advantage when compared to AMD3100 as no paradoxical signaling through CXCR4 would be elicited. Clinical studies are currently undergoing in solid tumors, while T140 has not been currently tested further in hematologic malignancies.
Given their role in promoting tissue invasion and cancer metastasization in preclinical studies, MMPs have also been at the centre of pharmacologic research as potential oncologic drugs [124, 125] . Unfortunately, multiple clinical trials with MMP inhibitors have been largely unsatisfactory, prompting further bench research to better understand the role of specific MMP in cancer progression and metastatic seeding, in order to design more effective treatments [126] .
CONCLUSIONS
AND FUTURE PERSPECTIVES
MM typically present with multiple distant sites of bone disease and the presence of circulating malignant cells at the time of diagnosis appears to be a common phenomenon. The process by which MM cells exit the bone marrow, enter venous circulation and home to a distant bone marrow site in accordance to a chemotactic gradient is collectively known as trafficking. Given the protective environment provided by the bone marrow niche, disrupting trafficking and homing is a promising therapeutic intervention to improve sensitivity to standard and novel chemotherapy drugs.
The SDF-1 antagonist AMD3100 has been proven safe in clinical trials as a tool to help mobilization of HSC in patients with hematologic malignancies; including MM. Preclinical studies in vitro and in vivo suggest this molecule to be effective in mobilizing MM cells and in increasing sensitivity to several anti-MM agents, including bortezomib.
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The fact that the extent of circulating malignant cells in newly diagnosed MM patients was found to be a poor prognostic factor and a marker of advanced, aggressive disease raises concerns that the mobilization of MM cells outside the bone marrow by AMD3100 could potentially be detrimental. As the CXCR4-SDF-1 axis is also implicated in retention of HSC to the bone marrow, combined treatment with AMD3100 and chemotherapy agents could theoretically results in more severe bone marrow suppression.
Data from mouse models showed that AMD3100 treatment did not cause more aggressive disease or increased extramedullary engraftment of MM cells. Moreover, combined treatment with bortezomib resulted in a significant percentage of mobilized MM cells to undergo apoptosis in the peripheral blood and no significant additional toxicity on HSC was noticed. Phase I/II clinical trials of AMD3100 and bortezomib in relapsed refractory MM patients are currently enrolling and results will help clarify these questions.
It is evident that additional knowledge of the mechanisms underlying homing and trafficking of MM cells is of pivotal importance in order to identify novel targets, design more effective therapies and aid in the quest for the cure of MM.
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